Nadh (nicotinamide adenine dinucleotide)

Suggested dosing of Nicotinamide adenine dinucleotide (NADH)

 

Nutrition & Energy Enhancement

2.5-5 mg PO qDay-qODay

 

Alzheimer's Disease

10-15 mg PO qDay-qODay

 

Parkinson's Disease

10-15 mg PO qDay-qODay

 

Chronic Fatigue Syndrome

10-15 mg PO qDay-qODay

 

Suggested uses of Nicotinamide adenine dinucleotide (NADH)

Chronic fatigue syndrome, improving mental clarity, alertness, and concentration, depression, jet lag, hypertension

Parkinson's disease, Alzheimer's disease

 

Efficacy

Insufficient information; positive results only from pilot studies or open-label studies

Dementia: Ineffective for mild to mod dementia from Alzheimer's

 

Nicotinamide adenine dinucleotide (NADH) adverse (side) effects

None reported

 

Warnings

Contraindications

Hypersensitivity to any component of oral product

 

Pregnancy and lactation

Pregnancy category: N/A

Lactation: N/A

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Nicotinamide adenine dinucleotide (NADH)

Metabolism: N/A

Excretion: N/A

 

Mechanism of action

Coenzyme involved in ATP production (glycolysis, citric acid cycle, electron transport chain)

May increase tyrosine hydroxylase-mediated dopamine production